Additionally, SAHA and olaparib showed synergistic therapeutic effects on prostate cancer cell death, apoptosis and DNA damage by decreasing the protein levels of BRCA1 and RAD51, while have no effect on normal prostate epithelial cells [31]. Here, BRCA1 is linked to prostate carcinoma.